<?xml version="1.0" encoding="UTF-8"?>
<ref id="B71">
 <label>71.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Senzer</surname>
    <given-names>N</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Barve</surname>
    <given-names>M</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Nemunaitis</surname>
    <given-names>J</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Long term follow up: Phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer</article-title>. 
  <source>J. Vacc. Vaccin.</source>
  <volume>4</volume>(
  <issue>8</issue>), 
  <fpage>209</fpage> (
  <year>2013</year>).
 </mixed-citation>
</ref>
